Skip to main content
Top
Published in: Familial Cancer 1/2023

02-06-2022 | Gastroesophageal Reflux Disease | Original Article

Prevalence and risk factors of barrett’s esophagus in lynch syndrome

Authors: Natalie Farha, Ruishen Lyu, David Liska, Amit Bhatt, Carole Macaron, Carol A. Burke

Published in: Familial Cancer | Issue 1/2023

Login to get access

Abstract

Lynch syndrome (LS), the most common hereditary cause of colorectal cancer, predisposes to upper gastrointestinal neoplasia. The prevalence of Barrett’s esophagus (BE) is elevated in some hereditary gastrointestinal cancer syndromes but has not been systematically evaluated in LS. We assessed the prevalence of BE, BE-related dysplasia, esophageal adenocarcinoma (EAC), and factors associated with BE in LS. Asymptomatic patients with a germline pathogenic variant (PV) in the DNA mismatch repair (MMR) genes undergoing EGD for LS surveillance were identified from a hereditary colorectal cancer registry. We assessed the prevalence of BE and compared demographic, clinical, and endoscopic factors in LS patients with and without BE by logistic regression analysis. 323 patients were included. 21 patients (6.5%) were diagnosed with BE including 38% of females and 33% without gastroesophageal reflux disease (GERD). Dysplasia was diagnosed in two patients (9.5%) and EAC in one (4.8%) patient. Factors associated with BE included male gender (OR 3.00, 1.21–7.46), age at last LS EGD (OR 1.04, 1.01–1.08), presence of hiatal hernia (OR 20.09, 4.57–88.23), hiatal hernia > 3 cm (OR 11.25, 2.41–51.94), and GERD (OR 3.39, 1.32–8.67). No MMR PV was associated with BE. BE was diagnosed in 1 of 15 patients undergoing EGD surveillance for LS and nearly 10% had dysplasia including one EAC. Risk factors associated with BE in LS are similar to those established for BE in the general population. More studies are needed to evaluate if an association between BE and LS exists.
Literature
Metadata
Title
Prevalence and risk factors of barrett’s esophagus in lynch syndrome
Authors
Natalie Farha
Ruishen Lyu
David Liska
Amit Bhatt
Carole Macaron
Carol A. Burke
Publication date
02-06-2022
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2023
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-022-00298-w

Other articles of this Issue 1/2023

Familial Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine